血清NOX4 MUC1表达水平与Ⅲ期非小细胞肺癌患者放疗疗效及随访1年总生存率的关系研究

doi:10.3969/j.issn.1006-6233.2024.12.016

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1351 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 研究血清还原型烟酰胺腺嘌呤二核苷酸磷酸氧化酶4(NOX4)、黏蛋白1(MUC1)表达水平与Ⅲ期非小细胞肺癌(NSCLC)患者放疗疗效及随访1年总生存率的关系。方法: 选取2020年4月至2023年3月我院收治的102例Ⅲ期NSCLC患者,均进行放疗干预,并在放疗前检测血清NOX4、MUC1水平,另选择51例健康志愿者作为对照,比较两组血清NOX4、MUC1水平,以及放疗前不同临床特征的Ⅲ期NSCLC患者血清NOX4、MUC1水平。根据放疗效果将Ⅲ期NSCLC患者分为疗效良好组和疗效不佳组,对比两组血清NOX4、MUC1水平。所有患者均进行随访,以中位血清NOX4、MUC1水平为界,比较不同血清NOX4、MUC1水平的患者1年总生存率,并采用单因素和多因素Cox回归分析Ⅲ期NSCLC患者1年生存的影响因素。结果: NSCLC组血清NOX4、MUC1水平均高于对照组(P<0.05)。放疗前不同性别、年龄、体质指数(BMI)、肿瘤位置、肿瘤最大直径、病理分型的Ⅲ期NSCLC患者血清NOX4、MUC1水平比较差异均无统计学意义(P>0.05)。本次102例Ⅲ期NSCLC患者放疗结果显示,疗效良好组例数为55例,疗效不佳组例数为47例。疗效良好组血清NOX4、MUC1水平低于疗效不佳组(P<0.05)。高水平NOX4组患者1年总生存率低于低水平NOX4组(P<0.05),高水平MUC1组患者1年总生存率低于低水平MUC1组(P<0.05)。单因素和多因素Cox回归分析结果显示,血清NOX4、MUC1水平是Ⅲ期NSCLC患者放疗后1年生存的影响因素(P<0.05)。结论: Ⅲ期NSCLC患者血清NOX4、MUC1表达水平与其放疗疗效及随访1年总生存率有关,检测血清NOX4、MUC1水平有利于辅助评估患者放疗疗效和早期预后生存情况。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	陆珏
	蔡梦娇
	张莹冰

关键词 ：非小细胞肺癌, Ⅲ期, 放疗, 还原型烟酰胺腺嘌呤二核苷酸磷酸氧化酶4, 黏蛋白1

Abstract：Objective: To study the relationship between expression levels of serum nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 4 (NOX4) and mucin 1 (MUC1) with radiotherapy efficacy and overall survival rate of 1-year follow-up in patients with stage Ⅲ non-small cell lung cancer (NSCLC). Methods: Totally 102 patients with stage Ⅲ NSCLC in the hospital from April 2020 to March 2023 were selected for radiotherapy intervention, and serum NOX4 and MUC1 levels were detected before radiotherapy. Another 51 healthy volunteers were selected as controls. Before radiotherapy, the inter-group levels of serum NOX4 and MUC1 were compared, and the intra-class levels of serum NOX4 and MUC1 in patients stage Ⅲ NSCLC with different clinical characteristics were assessed. According to the radiotherapy effect, patients with stage Ⅲ NSCLC were divided into good efficacy group and poor efficacy group, and the levels of serum NOX4 and MUC1 were compared after radiotherapy. All patients were followed up, and the 1-year overall survival rates of different patients were compared using the median levels of serum NOX4 and MUC1. Univariate and multivariate Cox regression analyses were used to analyze the influencing factors of 1-year survival rate in patients with stage Ⅲ NSCLC. Results: The levels of serum NOX4 and MUC1 in NSCLC group were significantly higher than those in control group (P<0.05). There were no statistical differences in serum NOX4 and MUC1 levels among stage Ⅲ NSCLC patients with different genders, ages, body mass index (BMI) values, tumor locations, maximum tumor diameters and pathological types before radiotherapy (P>0.05). Among 102 patients with stage Ⅲ NSCLC, the radiotherapy results showed that 55 patients were in the good efficacy group and 47 patients were in the poor efficacy group. Serum levels of NOX4 and MUC1 in good efficacy group were significantly lower than those in poor efficacy group (P<0.05). The 1-year overall survival rate in high-level NOX4 group was significantly lower than that in low-level NOX4 group (P<0.05), which in high-level MUC1 group was significantly lower than that in low-level MUC1 group (P<0.05). Univariate and multivariate Cox regression analyses showed that serum NOX4 and MUC1 levels were the influencing factors of 1-year survival rate in patients with stage Ⅲ NSCLC after radiotherapy (P<0.05). Conclusion: The expression levels of serum NOX4 and MUC1 in patients with stage Ⅲ NSCLC are related to the radiotherapy efficacy and overall survival rate after one year of follow-up. The detection of serum NOX4 and MUC1 levels is helpful to evaluate the radiotherapy efficacy and early prognosis survival.

Key words： Non-small cell lung cancer Stage Ⅲ Radiotherapy Reduced nicotinamide adenine dinucleotide phosphate oxidase 4 Mucin 1

基金资助:陕西省自然科学基础研究计划项目,(编号:2019JM-553)

通讯作者: 张莹冰

引用本文:

陆珏, 蔡梦娇, 张莹冰. 血清NOX4 MUC1表达水平与Ⅲ期非小细胞肺癌患者放疗疗效及随访1年总生存率的关系研究[J]. 河北医学, 2024, 30(12): 2028-2033.
LU Jue, CAI Mengjiao, ZHANG Yingbing. Relationship between Expression Levels of Serum NOX4 and MUC1 with Radiotherapy Efficacy and 1-Year Overall Survival Rate in Patients with Stage Ⅲ Non-Small Cell Lung Cancer. HeBei Med, 2024, 30(12): 2028-2033.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2024.12.016 或 http://www.hbyxzzs.cn/CN/Y2024/V30/I12/2028

[1] 胡惠东,刘聪,李鸣浩,等.不同治疗模式下局部晚期不可切除NSCLC患者血细胞计数临床意义[J].中华肿瘤防治杂志,2024,31(3):152-159.
[2] 刘小洁,黄俊星.NADPH氧化酶2在恶性肿瘤中的研究进展[J].国际肿瘤学杂志,2023,50(10):618-621.
[3] Chowdhury P,Kim S,Lee E S,et al.DNA micelle-templated copper nanoclusters for fluorescent imaging of MUC1-positive cancer cells[J].Microchimica Acta,2022,189(11):1-8.
[4] 许莉莉,高雅然,任晓玲,等.NADPH氧化酶及其抑制剂与脑缺血再灌注损伤[J].国际神经病学神经外科学杂志,2021,48(6):554-558.
[5] 郭丽,韩晨阳.还原型烟酰胺腺嘌呤二核苷酸磷酸(NADPH)氧化酶4(NOX4)在肝癌细胞诱导巨噬细胞M2型极化中的作用[J].中华微生物学和免疫学杂志,2020,40(12):934-940.
[6] 邱炜庆,汪文明,于海文.小白菊内酯通过下调NOX4抑制结肠癌SW480细胞增殖和侵袭[J].中国药师,2020,23(1):39-44.
[7] Zhang C,Wang Y,Liao W,et al.MUC1 deficiency induces the nasal epithelial barrier dysfunction via RBFOX3 shortage augment ubiquitin-proteasomal degradation in allergic rhinitis pathogenesis[J].Allergy,2022,77(5):1596-1599.
[8] Panasiuk M,Zimmer K,Czarnota A,et al.Chimeric virus-like particles presenting tumour-associated MUC1 epitope result in high titers of specific IgG antibodies in the presence of squalene oil-in-water adjuvant:towards safe cancer immunotherapy[J].Journal of nanobiotechnology,2022,20(1):160.
[9] 付红艳,王义勇,周凤,等.MUC1基因及蛋白表达在非小细胞肺癌中的临床意义[J].重庆医科大学学报,2020,45(6):764-769.
[10] 王艳,郑末,王硕莹,等.非小细胞肺癌组织中上皮钙黏着蛋白,黏蛋白1,PINCH mRNA的表达变化及其临床意义[J].山东医药,2020,60(6):61-64.
[11] 牛子捷,王军,肖洋,等.活性氧与恶性肿瘤的关系[J].国际耳鼻咽喉头颈外科杂志,2020,44(3):150-153.
[12] Takahashi Y,Tsutsumi Y,Takeuchi C,et al.Nuclear staining of claudin-18 is a new immunohistochemical marker for diagnosing intramucosal well-differentiated gastric adenocarcinoma[J].Pathology international,2020,70(9):644-652.